24/7 Market News Snapshot 15 October, 2024 – Lipella Pharmaceuticals Inc. Common Stock (NASDAQ:LIPO)

October 15, 2024

DENVER, Colo., 15 October, 2024 (247marketnews.com) – (NASDAQ:LIPO) are discussed in this article.
Lipella Pharmaceuticals Inc. has experienced a significant surge in pre-market trading, with shares rising 27.48% to $0.521, reflecting strong investor enthusiasm and a trading volume of 5.23 million. This upward momentum aligns with recent positive developments concerning the company’s innovative therapeutics portfolio.

In a noteworthy announcement, Lipella has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The newly granted U.S. Patent No. 17/829,960, titled “Delivery of Agents Using Metastable Liposomes,” encapsulates key advancements that facilitate precise, targeted delivery of therapeutic agents. This groundbreaking platform is poised to enhance treatment safety and efficacy, especially in critical therapeutic areas such as oncology and immunotherapy.

Dr. Michael Chancellor, the Chief Medical Officer of Lipella Pharmaceuticals, highlighted the strategic significance of this patent allowance, reinforcing the company’s intellectual property portfolio. He stated, “This milestone supports our ongoing efforts to address conditions such as hemorrhagic cystitis and oral lichen planus, by effectively targeting disease sites and minimizing systemic side effects.”

The implications of this technology extend to Lipella’s lead clinical assets, LP-10 and LP-310, which are currently undergoing Phase 2 trials. LP-10 is aimed at treating hemorrhagic cystitis—a serious condition often caused by chemotherapy, while LP-310 targets oral lichen planus, a chronic autoimmune ailment affecting millions.

With additional patents securing its formulations in multiple regions through 2035, Lipella is strategically positioned for substantial growth. The recent achievements not only highlight the company’s dedication to addressing unmet medical needs but also signify a transformative advancement in delivering therapeutic solutions globally.

Related news for (LIPO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.